Mr. Ogden has served as our Chief Financial Officer, Treasurer and Secretary since May 2009. He has over 20 years senior financial management experience with micro-cap entities. Mr. Ogden began his career as a public accountant with PricewaterhouseCoopers LLP and is a CPA.

Dr. Schneider has served as our Chief Executive Officer and as a member of our Board since January 2013. From 2009 to 2010, he was employed by Pfizer as Executive Vice President & R&D Integration Lead. From 1972-2009, he was employed by Wyeth Research where he held numerous senior-level R&D positions, including Executive Vice President & Chief of Operations and Senior Vice President, Research Operations & Planning.

Dr. Dinarello has served as our Chief Scientific Officer since March 2011 and served as our Acting Chief Executive Officer and a member of our Board from 2009 to 2011. He currently serves as Professor of Medicine and Immunology at the University of Colorado Denver. Dr. Dinarello is recognized as a "founding father" of cytokine biology and has received numerous US and international scientific awards in this area.

Dr. Forrest has served as a part-time business and scientific consultant since October 2012 and is leading our business development efforts with the current AAT manufacturers. As President of B D Forrest & Company, he consults with several biopharmaceutical companies in various therapeutic areas. Dr. Forrest brings over 25 year experience in immunology, drug development, and licensing and sales transactions.

Dr. Kamarck has served as a member of our Board and a consultant since January 2013. From 2010 to 2012, he was employed by Merck as President of Merck BioVentures and Senior Vice President of Vaccines and Biologics Manufacturing. From 2001 to 2009, he was employed by Wyeth and held various senior executive positions, including President, Technical Operations and Product Supply and was responsible for all global technical operations.